Biotech Startups
9,992 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
DemeRx develops psychedelic-based medications to treat addiction and mental health conditions. The company advances clinical trials for ibogaine and related compounds targeting alcohol use disorder and opioid addiction.
0 investors
DepYmed is a biotech company developing orally bioavailable small-molecule inhibitors of the enzyme PTP1B and copper-chelating compounds as therapeutics for cancer, rare diseases, and conditions such as Rett Syndrome and Wilson Disease. Its pipeline targets protein tyrosine phosphatase signaling pathways implicated in metabolic, inflammatory, and neurodegenerative diseases.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Diagnostic Biochips develops multichannel neural probes for extracellular recording in electrophysiology research, along with cloud-based software for spike sorting and analysis. It serves neuroscience researchers studying the brain at the neural network level.
0 investors
Dialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
0 investors
DiaMedica Therapeutics develops therapies aimed at reducing ischemia in patients with serious vascular diseases, with an initial focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. It is a clinical-stage biopharmaceutical company working on treatments for ischemic disorders.
0 investors
Equipment and manufacturing technology company providing continuous processing systems for lipid nanoparticles and other pharmaceutical nanoparticles.
0 investors
0 investors
0 investors
Diceros Therapeutics develops Verasone, a drug candidate combining two existing therapies for treatment of chronic rhinosinusitis via sinonasal irrigation. The company is advancing the treatment through clinical trials to provide improved efficacy and reduced side effects compared to existing options.
0 investors